GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands.
The main inhibitory neurotransmitter receptor of the brain, the gamma-aminobutyric acid type A receptor (GABA[A]), mediates the actions of several classes of clinically important drugs, such as benzodiazepines, barbiturates and general anaesthetics. This review summarizes the current knowledge on how classical benzodiazepines and novel nonbenzodiazepine compounds act on the benzodiazepine site of GABA(A) receptors and on their clinical pharmacology related to anxiolytic, sedative, hypnotic and cognitive effects or side-effects. Partial agonism, receptor subtype selectivity and novel binding sites are discussed as possible strategies to develop new drugs with fewer adverse effects than are seen in the clinical use of benzodiazepines.
Korpi
E R
ER
Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland. esa.korpi@utu.fi
Mattila
M J
MJ
Wisden
W
W
Lüddens
H
H
D001569:Benzodiazepines / Q000378:metabolism / Q000494:pharmacology*; D001665:Binding Sites; D006801:Humans; D006993:Hypnotics and Sedatives / Q000378:metabolism / Q000494:pharmacology; D008024:Ligands; D018377:Neurotransmitter Agents / Q000378:metabolism / Q000494:pharmacology; D011725:Pyridines / Q000378:metabolism / Q000494:pharmacology; D018079:Receptors, GABA / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D000077334:Zolpidem
D006993:Hypnotics and Sedatives; D008024:Ligands; D018377:Neurotransmitter Agents; D011725:Pyridines; D018079:Receptors, GABA; D001569:Benzodiazepines; D000077334:Zolpidem